U ncontrolled hypertension is associated with an increasing incidence of stroke, cardiovascular events such as myocardial infarction, peripheral artery disease, and end-stage renal disease across all ages, and ethnicities. [1] [2] [3] [4] [5] Detailed studies of blood pressure (BP) variability over 24 hours have further described an increased risk of cardiovascular events and stroke with elevated BP during the nighttime 6,7 and early morning hours.
U ncontrolled hypertension is associated with an increasing incidence of stroke, cardiovascular events such as myocardial infarction, peripheral artery disease, and end-stage renal disease across all ages, and ethnicities. [1] [2] [3] [4] [5] Detailed studies of blood pressure (BP) variability over 24 hours have further described an increased risk of cardiovascular events and stroke with elevated BP during the nighttime 6, 7 and early morning hours. 8, 9 The sympathetic nervous system plays an active role in the modulation of BP, and its overactivation can lead to hypertension. 10, 11 Percutaneous catheter-based renal denervation (RDN) by radiofrequency ablation of the renal artery nerves has been shown to reduce central sympathetic activity 12, 13 and BP in patients with uncontrolled hypertension. Although recently reported results from the Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3) 14 and SYMPLICITY HTN-Japan (HTN-Japan) 15 clinical trials did not demonstrate superiority of RDN over pharmacological management of hypertension based on superiority analyses of office BP or 24-hour ambulatory BP measurements (ABPM), 14, 15 further evaluation of the SYMPLICITY HTN-3 trial identified several potential confounding factors that may have impacted the overall results, including insufficient ablation attempts, insufficient 4-quadrant ablations, and antihypertensive medication changes. 16 In contrast to the results of SYMPLICITY HTN-3, the recently reported prospective Renal Denervation for Hypertension (DENER HTN) 17 trial reported small but statistically significant reductions in ambulatory BP (though not office or home BP) in denervated patients compared with a nonblinded, randomized control group of patients with resistant hypertension treated with a stepped-care pharmacological strategy. These reductions included greater decreases in both daytime and nighttime ambulatory systolic BP in the denervated group.
Enrollment in the HTN-Japan trial was stopped after the public announcement of the SYMPLICITY HTN-3 trial results, after randomizing only 22 patients to RDN and 19 patients to control. Hence, the study was underpowered to demonstrate a significant difference between RDN and control patients. Despite this limitation, the results suggested a trend toward greater reduction in 24-hour BP (between-group difference of −6.2 mm Hg, 95% confidence interval, −13.2 to 0.9, P=0.087). Although SYMPLICITY HTN-3 did not meet superiority using the 5-mm Hg superiority margin, the difference between the 2 arms (2.0 mm Hg, P=0.22) suggested a similar numeric trend for greater reduction in the RDN arm. Based on this observation, we examined similarities and differences between the studies, including differences in medications and performance of the RDN procedure. Furthermore, the present analysis evaluated the combined study populations for the effect of RDN on ambulatory BP during discrete times, particularly early morning and nocturnal time periods. These time periods have been shown to be more sensitive to demonstrating cardiovascular risk reduction, including risk of death and stroke, than decreases in office-measured BP 18, 19 and therefore might demonstrate a greater response to RDN.
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Methods
Study Designs
The design and 6-month outcomes of SYMPLICITY HTN-3, including ABPM methodology and outcomes, have been previously reported. 14, 20, 21 Both SYMPLICITY HTN-3 and HTN-Japan are prospective, multicenter studies conducted in the United States and Japan, respectively. Each study enrolled patients with baseline office systolic BP ≥160 mm Hg and 24-hour ambulatory systolic BP ≥135 mm Hg despite a stable prescribed antihypertensive drug regimen that included maximally tolerated doses of at least 3 antihypertensive medication classes, including a diuretic. Both studies had similar exclusion criteria, including patients with an estimated glomerular filtration rate <45 mL/min per 1.73 m 2 . The SYMPLICITY HTN-3 trial randomized patients 2:1 to RDN or sham control, whereas the HTN-Japan trial 15 randomized patients 1:1 to RDN or non-blinded standard-of-care control.
Ambulatory Blood Pressure Measurements
ABPM were performed with the Spacelabs 24 Ambulatory Blood Pressure Monitoring System (Spacelabs Healthcare, Snoqualmie, WA) in SYMPLICITY HTN-3 and with the TM-2431 Ambulatory Blood Pressure Monitoring System (A&D Company, Limited, Tokyo, Japan) in HTN-Japan. In both studies, an ABPM was performed every 30 minutes throughout the day and night. Both trials were approved by the Institutional Review Board for each site, and all patients provided written informed consent.
Only subjects with 24-hour readings that included 21 daytime and 12 nighttime readings were included in this analysis based on previously defined time periods in SYMPLICITY HTN-3 (7:00 AM and 9:59 PM daytime and 10:00 PM and 6:59 AM nighttime). 21 Therefore, this pooled analysis includes 386 patients treated with RDN (364 from SYMPLICITY HTN-3 and 22 from HTN-Japan) and 190 patients in the control group (171 from SYMPLICITY HTN-3 and 19 from HTN-Japan). The morning, daytime, and nighttime time periods in this analysis of both SYMPLICITY HTN-3 and the pooled population were defined as 6:00 to 8:59 AM, 9:00 AM to 8:59 PM, and 1:00 to 5:59 AM, respectively, as previously described. 22 Maximum, minimum, moving peak, mean peak, and mean surge were included as defined previously. 23 Moving peak morning BP was defined as the highest 1 hour moving average of 3 consecutive BP readings over the morning time period. Average peak nighttime BP was defined as the average of the 3 highest measurements over the nighttime interval (1:00-5:59 AM).
Renal Denervation Procedure
The 6-month change in systolic BP based on the number of 4-quadrant ablations (determined by at least 1 superior, inferior, posterior, and anterior treatment in either the left or right renal artery) in SYMPLICITY HTN-3 has been previously published. 16 We include here an analysis of the 6-month change in morning systolic BP based on the number of 4-quadrant ablations. Given the limited number of patients in HTN-Japan, patients with 1 (in either left or right) and 2 (in both the left and the right) renal arteries treated with 4-quadrant ablations were combined (denoted as at least 1 four-quadrant ablation) and compared with patients with no 4-quadrant ablations.
Statistical Analysis
All analyses were based on the intent-to-treat principle. Continuous variables are presented as mean±standard deviation, and betweengroup differences were compared using the t test or Wilcoxon ranksum test as appropriate. Within-group differences from baseline to follow-up were assessed using the paired t test. Categorical variables were presented as counts and percentages and were compared using the Fisher exact test and the χ 2 test for multilevel variables. Multivariate stepwise linear regression analysis was conducted to assess independent correlates of the 6-month change in morning and also nighttime systolic BP with entry/stay significance levels of 0.1/0.1. This analysis was conducted on both the SYMPLICITY HTN-3 and the pooled (SYMPLICITY HTN-3 and HTN-Japan) populations and tested among patients in the RDN group and separately in the control group. The following baseline characteristics were considered: baseline morning BP (in the morning BP model), baseline nighttime BP (in the nighttime BP model), age, history of type II diabetes mellitus, estimated glomerular filtration rate ≥60 mL/min per 1.73 m 2 , male sex, number of antihypertensive medications, number of classes of antihypertensive medications, as well as baseline prescription of different classes of antihypertensive drugs. The following RDN procedural variables were also included in the multivariable analyses of the RDN arm: total number of ablation attempts, total number of complete 120-s ablation attempts, and number of arteries with 4-quadrant ablation attempts.
We tested for the heterogeneity of the treatment effect using a multivariate model with 6-month BP change as the dependent variable and study, treatment, and the study by treatment interaction as the independent variables. The interaction term was not significant (P=0.69). Therefore, we think there is no evidence of heterogeneity, allowing us to pool the SYMPLICITY HTN-3 and HTN-Japan trials.
All analyses were performed using SAS version 9.1 or higher (SAS Institute, Inc, Cary, NC). P values <0.05 were considered statistically significant.
Results
Patient Disposition
A total of 576 patients were included in the pooled analysis (535 in SYMPLICITY HTN-3 and 41 in HTN-Japan). Data from 372 RDN patients (347 with ABPM) and 188 control patients (178 patients with ABPM) were available at 6 months ( Figure S1 in appendix in the online-only Data Supplement). Table 1 provides baseline patient and procedure characteristics for SYMPLICITY HTN-3 versus HTN-Japan (RDN and control combined), as well as the pooled cohort (RDN versus control). Patients in SYMPLICITY HTN-3 had a higher body mass index and were more likely to have a history of obstructive sleep apnea than patients in HTN-Japan. No differences in baseline characteristics in the pooled analysis were observed
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between patients treated with RDN and control patients. Likewise, no differences were observed in the pooled analysis between groups in baseline office and ambulatory morning, daytime, or nighttime systolic BP (Table 2) . Table S1 provides antihypertensive medication use at baseline in SYMPLICITY HTN-3 versus HTN-Japan and in the pooled analysis in patients treated with RDN versus control. There was no difference at baseline in the number of antihypertensive medications prescribed in SYMPLICITY HTN-3 versus HTN-Japan (5.2±1.4 versus 4.9±1.6, P=0.28). However, the choice of medication classes differed by study. As compared with HTN-Japan, patients in SYMPLICITY HTN-3 were more likely to be prescribed an α-2 antagonist, angiotensinconverting enzyme inhibitor, and vasodilator and less likely to be prescribed an aldosterone antagonist, α-1 blocker, angiotensin receptor blocker, and calcium channel blocker. The number of antihypertensive medications and specific classes prescribed were similar among patients treated with RDN versus control in the pooled analysis. 
Antihypertensive Medications
Renal Denervation Procedure
Blood Pressure Outcomes
Patients in HTN-Japan with at least 1 four-quadrant ablation (n=18) had a numerically greater 6-month change in morning systolic BP Figure 1A ). This same relationship was observed in the pooled analysis for mean morning (−7.3±19. Figure 1B) . Also, in both SYMPLICITY HTN-3 ( Figure 2A ) and the pooled analysis ( Figure 2B ), RDNtreated patients experienced a significantly greater change in mean peak, maximum, and minimum nighttime systolic BP, as well as maximum and moving peak morning systolic BP. No differences in morning or nighttime surge in either SYMPLICITY HTN-3 or the pooled analysis were observed (Table 3) .
Multivariate Analysis
A multivariate analysis was conducted to determine predictors of both morning and nighttime systolic BP among patients in both SYMPLICITY HTN-3 and the pooled population (Table 4 ). Higher baseline morning (and nighttime) systolic BP was associated with a greater 6-month reduction in morning (and nighttime) systolic BP. Additionally, higher baseline estimated glomerular filtration rate and prescription of an aldosterone antagonist were associated with a greater 6-month reduction nighttime systolic BP in the RDN cohort.
Discussion
Compared with the control group at 6 months postrandomization, RDN was associated with a significantly greater reduction in both morning and nocturnal systolic BP but not daytime systolic BP in treatment-resistant hypertensive patients in both the original SYMPLICITY HTN-3 cohort and in a pooled cohort of SYMPLICITY HTN-3 and HTN-Japan. Additionally, patients receiving RDN had significantly lower maximum, minimum, and mean peak nighttime systolic BP, as well as maximum and moving peak morning systolic BP compared with control patients. Taken together, these findings imply that a more sensitive analysis of response to RDN 
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December 2015 restricted to select diurnal periods when sympathetic tone is high suggests a significant impact of RDN on ambulatory BP. In addition, the systolic BP reduction during these times of high sympathetic tone and clinical events suggests the hypothesis that RDN might reduce cardiovascular risk in hypertensive patients.
For this analysis, we specifically restricted the definition of morning to the early morning (6:00-8:59 AM) because cardiovascular events are most likely to occur during this time. 24 Early morning systolic BP 9 (ie, when morning activities begin) is the strongest predictor of cardiovascular events. 8 We used a 24-hour average of systolic BP during the morning 
P=0.018
Mean Peak N=325 N=159 -6.5 ±19.9 -0.9 ±20.8
P=0.004
Mean Peak N=347 N=178 period to define morning BP, as suggested by recent work. 8, 22, 23 In the Home Blood Pressure Measurement With Olmesartan Naïve Patients to Establish Standard Target Blood Pressure (HONEST) study, the risk of cardiovascular events was significantly higher in patients with morning systolic BP ≥145 mm Hg and office systolic BP <130 mm Hg (hazard ratio 2.47 for cardiovascular events) than in patients with morning systolic BP <125 mm Hg and office systolic BP ≥150 mm Hg (hazard ratio 0.87). 25 The association of high systolic BP and cardiovascular risk is greatest in the morning than any other time of day, 26 and control of morning systolic BP is important for reducing cardiovascular events. Nighttime BP also has a stronger association with hypertensive target organ damage, cardiovascular events, and stroke as compared with daytime BP, 6, 7, 27, 28 and nondipping patterns are associated with increased cardiovascular risk. 29 Nighttime BP was also defined in this analysis using a more restrictive time window (1:00-5:59 AM), based on the European Society of Hypertension practice guidelines for ABPM. 22 These restrictions were adopted to exclude the BP variability introduced by different behaviors of individual patients and may thus best define sleep ambulatory BP, a time period predictive of neurological events. Twenty-four-hour clock-defined nighttime BP has been found to be slightly higher than sleep ambulatory BP 6 and does not give an accurate representation of sleeping BP when the time interval is too long. This difference in defining day and night periods for ABPM accounts for the differing results between the current post hoc analysis and the prior prespecified analysis of ambulatory BP data for SYMPLICITY HTN-3. 21 Additionally, because antihypertensive medications are typically taken during the daytime, they may be less effective during sleeping hours when plasma levels are lowest. In a meta-analysis of studies analyzing the effect of antihypertensive drugs on both office and 24-hour ambulatory BP, the effect on the reduction of 24-hour ambulatory BP was smaller than that in the office because of substantially less reduction in nighttime as compared with daytime BP. 30 Patients in HTN-Japan had a lower body mass index and, perhaps related to this, were less likely to have a history of obstructive sleep apnea compared with patients in SYMPLICITY HTN-3. Asian patients on average have a lower body mass index and have different associations between body mass index, body fat percentage, and health risks compared with an American population. [31] [32] [33] It is unclear whether the pathophysiology of patients, including the role of sympathetic tone, in treatment-resistant, uncontrolled hypertension could be different in Asian patients. However, regardless of inherent racial differences, differences also existed between the 2 studies in terms of medications prescribed and the RDN procedure. Although patients in both SYMPLICITY HTN-3 and HTN-Japan received a similar number of antihypertensive medications, between baseline and 6 months, 39% of patients in SYMPLICITY HTN-3 underwent antihypertensive medication changes, 16 whereas only 7.3% of patients in HTN-Japan underwent antihypertensive medication changes (2 were in the RDN group and 1 was a control patient). 15 Some previous studies have examined the impact of RDN therapy on ABPM and its derived components. Significant decreases in mean 24-hour systolic BP were reported in a subset of 20 RDN patients as compared with 25 control patients in the SYMPLICITY HTN-2 trial. 34 Other derived indices of ABPM were not reported. Mahfoud et al 35 performed a retrospective multicenter meta-analysis of changes in 24-hour BP after RDN. In the subset of 303 patients with true treatmentresistant hypertension (ie, excluding white coat hypertension), significant decreases in daytime, nighttime, 24-hour, maximal, and minimal daily systolic BP were observed. In a related study, Zuern et al 36 reported significant improvements 
Limitations
There are several limitations of this analysis. The present analysis pooled data from 2 clinical trials with similar inclusion criteria but different study designs. In particular, the control group in SYMPLICITY HTN-Japan was not blinded and did not undergo a sham procedure. However, ABPM may not be as sensitive as office measurements to potential placebo effects because measurements are automated and consist of up to 48 individual measurements recorded over 24 hours. The definitions of morning, daytime, and nighttime used in our analysis were not prespecified. However, these time points were chosen to ensure a greater likelihood that nighttime was specific to sleeping hours and were based on prior publications 18, 19 in which these specific time periods were more predictive of impact of treatment on cardiovascular risk.
Perspectives
We used more specific windows to define morning and nighttime BP that more closely match the rising hours of the morning and the sleeping hours of the night. In both SYMPLICITY HTN-3 alone and in this pooled analysis of SYMPLICITY HTN-3 and HTN-Japan, RDN, as compared with control, resulted in a significant 6-month reduction in morning, nighttime, and peak nighttime systolic BP, but not daytime systolic BP. Given that morning and nighttime are associated with high sympathetic tone and are the highest risk periods for cardiovascular events, these findings suggest not only a potential treatment effect at times of peak sympathetic activity but also the potential ability of RDN to blunt the circadian BP variation. Our findings have important implications for the design of future RDN studies. With revised procedural guidelines [37] [38] [39] (including more 4-quadrant ablations and stricter oversight of medication adherence), we hope to see a greater decline in these parameters as well as in overall 24-hour ambulatory BP, raising the possibility that a clinically significant reduction in cardiovascular events might follow RDN treatment, although this will need to be proved in appropriately designed randomized trials. 
